Articles by Jalpa A. Doshi, PhD

Financial Incentives Tied to Medicare Star Ratings: Impact on Influenza Vaccination Uptake in Medicare Beneficiaries
ByBruce Stuart, PhD,F. Ellen Loh, PhD,Sachin Kamal-Bahl, PhD,Jeffrey Vietri, PhD,Daniel Bakken, MBA,Justin Puckett, BA,Jalpa A. Doshi, PhD Influenza vaccine uptake improved among Medicare Advantage enrollees when influenza vaccination was introduced as a performance metric in Medicare star ratings and accompanying bonus payments.

Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of "Too Much Too Soon"
ByJalpa A. Doshi, PhD,Pengxiang Li, PhD,Amy R. Pettit, PhD,J. Samantha Dougherty, PhD,Ashley Flint, MPP,Vrushabh P. Ladage, BS Medicare claims analyses offer insight into how proposed policy changes would affect out-of-pocket prescription costs for Part D beneficiaries requiring specialty drugs.

Synchronized Prescription Refills and Medication Adherence: A Retrospective Claims Analysis
ByJalpa A. Doshi, PhD,Raymond Lim, MA,Pengxiang Li, PhD,Peinie P. Young, PharmD, BCACP,Victor F. Lawnicki, PhD,Andrea B. Troxel, ScD,Kevin G. Volpp, MD, PhD A retrospective claims analysis showed that synchronized refill schedules were associated with better medication adherence among Medicare Advantage patients taking multiple maintenance medications.

High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia
ByJalpa A. Doshi, PhD,Pengxiang Li, PhD,Hairong Huo, PhD, MS,Amy R. Pettit, PhD,Rishab Kumar,Brendan M. Weiss, MD,Scott F. Huntington, MD, MPH A Medicare claims analysis of patients newly diagnosed with chronic myeloid leukemia revealed that high cost sharing was associated with reduced and/or delayed tyrosine kinase inhibitor initiation under Part D.

Impact of Cost Sharing on Specialty Drug Utilization and Outcomes: A Review of the Evidence and Future Directions
ByJalpa A. Doshi, PhD,Pengxiang Li, PhD,Vrushabh P. Ladage, BS,Amy R. Pettit, PhD,Erin A. Taylor, PhD, MSPH The authors review published evidence regarding associations between high cost sharing for specialty pharmaceuticals indicated for rheumatoid arthritis, multiple sclerosis, and cancer, and their utilization.

A Randomized Controlled Trial of Negative Co-Payments: The CHORD Trial
ByKevin G. Volpp, MD, PhD,Andrea B. Troxel, ScD,Judith A. Long, MD,Said A. Ibrahim, MD, MPH,Dina Appleby, MS,J. Otis Smith, EdD,Jalpa A. Doshi, PhD,Jane Jaskowiak, BSN, RN,Marie Helweg-Larsen, PhD,Stephen E. Kimmel, MD, MSCE This study extends value-based insurance design concepts in testing the impact on blood pressure control of rewards that provided negative co-payments for blood pressure medication.

A Randomized Controlled Trial of Co-Payment Elimination: The CHORD Trial
ByKevin G. Volpp, MD, PhD,Andrea B. Troxel, ScD,Judith A. Long, MD,Said A. Ibrahim, MD, MPH,Dina Appleby, MS,J. Otis Smith, EdD,Jane Jaskowiak, BSN, RN,Marie Helweg-Larsen, PhD,Jalpa A. Doshi, PhD,Stephen E. Kimmel, MD, MSCE This study tests the impact on blood pressure control of a reward that lowered co-payments for blood pressure medication to $0.

Impact of Cost-Sharing on Treatment Augmentation in Patients With Depression
ByTeresa B. Gibson, PhD,Yonghua Jing, PhD,Jill E. Bagalman, MSW,Zhun Cao, PhD,John A. Bates, PhD,Tony Hebden, PhD,Robert A. Forbes, PhD,Jalpa A. Doshi, PhD Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.
